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ABSTRACT
Aim: To assess mac-2-binding protein glycosylation isomer (M2BPGi) serum performance compared to liver 
biopsy in diagnosisng liver fibrosis
Method: Literature search using Pubmed ®, Ebsco®, ProQuest®, Scopus®, Clinical Key databases, and the 
Cochrane Library® yield four relevant and full-text articles. The four articles were critically appraised for its 
validity, importance, and applicability.
Results: Sensitivity and specificity in all four studies showed that M2BPGi serum was inadequate to ruling 
in and ruling out the diagnosis of liver fibrosis in chronic hepatitis B patients. The difference in M2BPGi cut-off 
value to determine the stage of fibrosis in each study makes this value cannot be used as an accurate standard 
to determine the advanced stage (F≥3) of liver fibrosis. On the other hand, M2BPGi serum combined with other 
tests are known to improve the diagnostic accuracy.
Conclusion: MBP2Gi serum cannot be used as a diagnostic modality for detecting liver fibrosis in chronic 
hepatitis B patients.
Keywords: hepatits B, fibrosis, mac-2-binding protein glycosylation isomer (M2BPGi), wisteria floribunda, 
liver biopsy
ABSTRAK
Tujuan: Untuk menilai performa diagnosis mac-2-binding protein glycosylation isomer (M2BPGi) 
dibandingkan dengan biopsi hati.
Metode: Pencarian literatur dengan menggunakan database Pubmed®, Ebsco®, ProQuest®, Scopus®, Clinical Key, 
dan Cochrane Library® yang menghasilkan empat artikel relevan dan full-text. Keempat artikel tersebut ditelaah dengan 
menggunakan kriteria validity, importance, dan applicability untuk menentukan derajaat kegunaan dalam studi ini.
Hasil: Sensitivitas dan spesifisitas pada keempat studi menunjukkan bahwa pemeriksaan M2BPGi masih 
belum memadai untuk mendeteksi (ruling in) dan menyingkirkan (ruling out) diagnosis fibrosis hati pada 
pasien hepatitis B kronik. Perbedaan nilai cut off M2BPGi untuk menentukan stadium fibrosis pada tiap studi, 
membuat nilai tersebut belum dapat langsung dijadikan standar yang akurat untuk menentukan stadium lanjut 
(F ≥ 3) fibrosis hati. Di sisi lain, pemeriksaan M2BPGi yang dikombinasikan dengan pemeriksaan lain diketahui 
meningkatkan akurasi diagnostik.
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Simpulan: MBP2Gi belum dapat dijadikan sebagai modalitas diagnosis untuk mendeteksi fibrosis hati pada 
pasien hepatitis B kronik.
Kata kunci: hepatitis B, fibrosis, mac-2-binding protein glycosylation isomer (M2BPGi), wisteria floribunda, 
biopsi hati
INTRODUCTION
Liver fibrosis is an excessive accumulation of 
extracellular matrix proteins which causes liver tissue 
turns into scar tissue, causing a decrease in liver function. 
Liver fibrosis occurs as a result of chronic damage to 
liver tissue, one of which is caused by chronic hepatitis 
B.1 It has become a global concern because more than 
240 million people in the world are infected to this 
virus.2 15% to 40% individuals who are untreated can 
progress to cirrhosis, which may lead to liver failure and 
liver cancer.3 Liver fibrosis severity can be categorized 
into F1-F4 staging.1 Hence, a clinician must conduct a 
useful diagnostic method to determine this condition.
Liver biopsy is the gold standard for diagnosing 
liver fibrosis and its staging. This method provides a 
clear picture of histopathology analysis. The biopsy 
is considered to be a gold standard because of its high 
accuracy.4 However, liver biopsy is an invasive diagnostic 
procedure, with 40% incidence of pain in patients and 
0.5% incidence of significant complications.5 Also, 
sampling errors can also occur primarily in small tissue.6
At present, there have been several studies showing 
that mac-2 binding protein glycosylation isomer 
(M2BPGi) serum or wisteria floribunda can diagnose 
liver fibrosis.7-10 M2BPGi is a serum secreted by 
the liver during the development of fibrosis. Using 
M2BPGi serum will reduce the risk of complications 
and shorten the time in diagnosing liver fibrosis. This 
report aims to determine the diagnostic performance 
of M2BPGi/wisteria floribunda in diagnosing liver 
fibrosis compared to liver biopsy.
CASE ILLUSTRATION
A 25 years-old male came to a hospital four months 
ago with the chief complaint of epigastric abdominal 
pain. He described that he often feels nauseous and 
sometimes vomit. There was also loss of appetite and 
an enlargement in the stomach. However, the patient 
never had yellow eyes dan brownish urine. During his 
adolescence, he used syringe drugs for about three years. 
Laboratory and PCR examination results are 
HBsAg (+), SGOT 155 U/L, SGPT 120 U/L, total 
bilirubin 0.84 mg/dL, direct bilirubin 0.13 mg/dL, and 
HBV-DNA (+). The doctor who treated him defines 
hepatitis B virus infection as his diagnosis. Hence the 
doctor ordered a liver biopsy examination to determine 
the patient liver’s fibrosis level. However, the patient 
refused to have a biopsy because it is an invasive 
procedure. A friend of the patient’s who visited him 
in the hospital told him that in Japan, where she lived, 
there was a new serum biomarker for detecting liver 
fibrosis. The doctor decided to study the new biomarker 
using the evidence-based medicine method.
ANSWERABLE CLINICAL QUESTION
In young adult patients who suspected having liver 
fibrosis in chronic hepatitis B infection, does M2BPGi 
serum biomarkers provide accurate and faster results 
when compared to biopsy methods in detecting liver 
fibrosis?
METHOD
The article searching was conducted on PubMed®, 
Ebsco®, ProQuest®, Scopus®, Clinical Key, and 
Cochrane® using the keywords “chronic hepatitis”, 
“M2BPGi”, “biopsy”, and “fibrosis” along with 
its synonyms which is combined using Boolean 
operations (Table 1). After the article search process 
completed, then the article selection process is carried 
out by screening title abstract, filtering duplication, and 
eligibility criteria as shown in the flowchart (Figure 1).
Table 1. Article searching strategy (done in September 19th, 2018)
Database Search terms Results
PubMed ((chronic hepatitis) AND ((M2BPGi OR 
(wisteria floribunda)))) AND ((biopsy 
OR (liver histology) AND ((fibrosis OR 
(fibrosis degree)))
31
Ebsco ((chronic hepatitis) AND ((M2BPGi OR 
(wisteria floribunda)))) AND ((biopsy 
OR (liver histology) AND ((fibrosis OR 
(fibrosis degree)))
18
ProQuest ((chronic hepatitis) AND ((M2BPGi OR 
(wisteria floribunda)))) AND ((biopsy 
OR (liver histology) AND ((fibrosis OR 
(fibrosis degree)))
48
Scopus ((chronic hepatitis) AND ((M2BPGi OR 
(wisteria floribunda)))) AND ((biopsy 
OR (liver histology) AND ((fibrosis OR 
(fibrosis degree)))
9
Clinical Key chronic hepatitis AND (M2BPGi OR 
(wisteria floribunda)) AND Fibrosis
1
Cochrane chronic hepatitis AND (M2BPGi OR 
(wisteria floribunda)) AND Fibrosis
0
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RESULTS
In Mak L et al study, there are 327 chronic hepatitis 
B patients with 54 patients have stage 3 or more liver 
fibrosis (> F3). The scoring system which is used to 
differentiate the stage of liver fibrosis is Ishak scoring 
system. The optimal cut off for serum M2BPGi is 
0.45 cut off index (COI) with sensitivity value 69.6%, 
specificity value 74.1%, positive predictive value 
(PPV) 23.1%, and negative predictive value (NPV) 
95.5%.7
In Jekarl DW et al study, there are 151 chronic 
hepatitis B patients with 15 patients have stage 3 
liver fibrosis (F3). The scoring system which is used 
to differentiate the stage of liver fibrosis is Knodell 
scoring system. Cut off for serum WFA-M2BP is 0.7 
with sensitivity value 73.3%, specificity value 62.5%, 
PPV 66.1%, and NPV 70.1%.8
In Nakamura M et al study, there are 91 chronic 
hepatitis B patients with 20 patients have stage 3 liver 
fibrosis (F3). The scoring system is also Knodell. The 
cut off value for serum WFA(+)-M2BP is >1 COI with 
sensitivity value 67%, specificity value 70%, PPV 
53%, and NPV 81%. Also in this study, a combination 
of serum WFA(+)-M2BP and serum miR-122 is 
perfomed which results in an increase of PPV and 
specificity value to 64% and 87%.9
In Ito K et al meta-analysis, 21 studies were 
written from January 2013 to September 2016. All 
these studies are in accordance with the determined 
eligibility criteria and sourced from the PubMed/
Medline and Cochrane databases.10 The quality of each 
study in this meta-analysis is assessed based on the 
quality assessment of studies of diagnostic accuracy 
included in systematic review (QUADAS-2). From 
Figure 1. Flow of Article Searching (done in September 19th, 2018)
Table 2. Validity, relevance, and level of evidence
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Mak et al 2018 2b + + ? 69,9 74,1 23,1 95,5 +
Jekarl et al 2018 2b + + + 73,3 62,5 66,1 70,1 +
Nakamura et al 2017 2b + + - 67 70 53 81 +
+ yes – no ? not mentioned
Author Year of pub.
Level of 
evidence PICO
Important 
studies imculed
Appropriate 
eligibility criteria
Validity of 
studies
Result 
similarity
Result’s forest 
plot
Ito et al 2017 1 + - + + - +
+ yes – no ? not mentioned
After the selection, critical appraisal was done using 
critical appraisal kit for diagnostic study and systematic 
review based on Center for Evidence-based-medicine 
(CEBM) University of Oxford. 
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Table 3. Characteristics of literatures
Literature Number of samples
Characteristics of 
samples Index test
Refe-
rence 
test
Outcome Advantages Disadvantages
Mak  et al7 327
(>F3 n=54) 
Mean age 38.1 
years old, men 
(70%), HbeAg + 
(62.1%), advanced 
fibrosis or early 
stage of cirrhosis 
(15.3%)
HISCL M2BPGi 
reagent kit on 
automated 
immunoana-
lyzer 
HISCL-800 
(Sysmex, 
Hyogo, Japan)
Liver 
biopsy
Diagnosis 
of  stage >3 
liver fibrosis in 
chronic hepatitis 
B patient
- Detect the 
effects of 
antiviral to 
M2BPGi levels,
- Examination 
is clearly  
presented and 
can be applied
- Large sample 
size
- Selection bias is 
minimal because 
of randomization 
- Asian population
M2BPGi test is not 
certain to be done 
blindy
Jekarl et al8 151
(F3 n=15)
Mean age 40 years 
old, men (72.5%), 
and  HBeAg-
positive (78%)
Automated 
chemilumi-
nescence 
enzyme 
immunoas-
say analyzer 
(HISCL-5000, 
Sysmex, Kobe, 
Japan)
Liver 
biopsy
Diagnosis of 
stage >3  liver 
fibrosis in 
chronic hepatitis 
B patient
- Examination 
is clearly  
presented and 
can be applied
- Large sample 
size
- Selection bias is 
minimal because 
of consecutive 
admissions 
- Liver biopsy and 
M2BPGi test are 
performed at 
one time (blind)
- Asian population
There are exclusion 
criterias which make 
hepatitis B patients 
are not all examined
Nakamura 
et al9
91
(F3 n=20)
Mean age 40 years 
old (between 25-68 
years old), men 
(72.5%),  HbeAg + 
(78%)
HISCL M2BPGi 
assay kit 
(Sysmex Co., 
Kobe, Japan)
Liver 
biopsy
Diagnosis of 
stage >3 liver 
fibrosis in 
chronic hepatitis 
B patient
- Examination 
is clearly  
presented and 
can be applied
- Selection bias is 
minimal because 
of consecutive 
admissions 
- Asian population
- Small sample size
- Not all samples  
  are examined by  
  both liver biopsy  
  and M2BPGi test
Ito 
et al10
(meta-
analysis)
21 studies 
(4772 
patients) 
with 5 
studies 
about 
hepatitis 
B (942 
patients and 
163 F3) 
-   Ishii et al.: 62% 
men, mean age 
44 years old
-   Ichikawa et 
al.: 64% men, 
mean age 47 
years old
-   Heo et al.: 73% 
men, mean age 
51 years old
-   Nishikawa et 
al.: 62% men, 
mean age 16 
years old
-   Zou et al.: 68% 
men and mean 
age 38 years old 
(training); 62% 
men and mean 
age 37 years old 
(validation)
HISCL M2BPGi 
assay kit
Liver 
biop-sy
Diagnosis of 
stage >3 liver 
fibrosis in 
chronic hepatitis 
B patient
- The aim of 
meta-analysis is 
clear
- Large sample 
size
- The quality 
of studies is 
measured by 
QUADAS-2 
criteria
- Evaluate the 
ability of WFA+-
M2BP to predict 
HCC and 
survival rate of 
HCC patients
- Forest plot is 
understand-able
-  There are 
inclusion and 
exclusion 
criterias which 
make literatures 
of hepatitis B 
patients and 
WFA+-M2BP 
examination 
can not be used 
entirely 
-  Not only Asian 
population
-  There is a 
significant 
heterogeneity 
(evaluated by Q 
Cochran test)
total 21 studies (4772 patients), there are 5 studies of 
hepatitis B patients (1066 patients) with 163 patients 
have stage 3 liver fibrosis (F3). The METAVIR 
evaluation system is used to differentiate the stage of 
liver fibrosis in this study. The mean sensitivity and 
specificity values  of WFA+-M2BP levels for stage 3 
liver fibrosis (F3) are 0.615 and 0.709. The cut off 
values for detecting hepatitis B patients' WFA+-M2BP 
levels are different for each study including 1.42 in 
Nishikawa study (2016), 1.40 in Ishii study (2016), 
and 1.26 in Ichikawa study (2016).
DISCUSSION
All four studies exhibit similarities in terms of 
patient spectrum and the reference test used. Patients 
in all studies also exhibit variety in terms of age range 
and stages of liver fibrosis diagnosed (ranging from 
F0 to F4), with biopsy and histopathological grading 
as the golden standard for diagnosis. However, unlike 
the other two studies, it was not clear whether blinding 
was conducted in the study by Mak et al and Nakamura 
et al, increasing the risk of bias in those two studies.7,9
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In diagnosing advanced liver fibrosis (≥ F3) among 
chronic hepatitis B patients, serum WFA-M2BPGi 
in all four studies show similar yet rather poor 
sensitivity and specificity (61,5-73,3% and 62,5-74,1%, 
consecutively). In other words, advanced liver fibrosis 
was successfully detected in only 61.5-73.3% patients 
and ruled out in only 62.4-74.1% patients, while the 
remaining patients were incorrectly diagnosed (false 
negative or false positive). This indicates that M2BPGi 
has yet to be a good modality in ruling on nor ruling 
out advanced liver fibrosis in chronic HBV patients. 
Nevertheless, study by Nakamura et al shows an 
increase in M2BPGi’s specificity to 87% when used in 
combination with serum microRNA-122 examination 
in diagnosing advanced liver fibrosis. This shows 
that combining M2BPGi with other diagnostic test 
may improve the overall sensitivity and specificity in 
diagnosing advanced liver fibrosis.9
In addition, studies by Mak et al, Jekari et al, and 
Nakamura et al show a variation in the PPV and NPV 
of M2BPGi (23.1-66.1% and 70.1-95.5% respectively). 
The lowest PPV (23.1%) and the highest NPV (95.5%) 
were found in the study by Mak et al, but this was due 
to the small sample size for the stage F ≥ 3 compared 
to other stages. Furthermore, despite being conducted 
in Asia (Korea and Japan), none of the studies actually 
states the prevalence of advanced liver fibrosis in 
chronic HBV patients in their respective countries. 
Comparison to the prevalence in Indonesia hence 
cannot be made and the predictive values cannot be 
used as reference in determining the diagnostic value 
of M2BPGI in the Indonesian population.7,8,9
Despite these findings, it is worth mentioning that 
the histopathological scoring system used differs 
in each study. Jekari et al and Nakamura et al used 
the Knodell scoring system, while Ito et al and Mak 
et al used METAVIR and Ishak scoring system 
respectively.7,8,10 Although these scoring systems 
overlap, there might be some discrepancies that 
affect the overall sensitivity and specificity. The cut-
off values of serum M2BPGi used to determine each 
stage of liver fibrosis in each study also differs. Stage 
F ≥ 3 was defined by the cut-off values of 1.26, 1.40, 
and 1.42 in the meta-analysis by Ito et al., ≥ 0,45 COI 
in the study by Mak et al, ≥0.7 COI in the study by 
Nakamura et al, and  ≥ 1 COI in the study by Nakamura 
et al. Scoring system and the range of cut-off values 
used need to be standardized in future studies to obtain 
more accurate sensitivity and specificity.
CONCLUSION
WFA-M2BPGi is novel serum marker currently 
being developed to diagnose various stages of liver 
fibrosis in chronic hepatitis B patients. Despite its 
growing availability in Indonesia, particularly in Cipto 
Mangunkusumo Hospital in Jakarta, based on the 
available studies, serum M2BPGi is yet to be a good 
modality in ruling in and ruling out advanced liver 
fibrosis (F ≥ 3) due to its rather poor sensitivity and 
specificity. The studies appraised also used different 
histopathological scoring systems as reference tests 
and varying, non-standardized M2BGPi cut-off 
values for each staging, compromising the accuracy 
of its sensitivity and specificity. However, combining 
serum M2BPGi with other examination may increase 
the overall sensitivity and specificity in diagnosing 
advanced liver fibrosis, as when M2BPGi was used in 
combination with serum microRNA-122 examination.
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